Study: Diabetes Drug May Cut Risk of Alzheimer’s and Parkinson’s by 20%
SGLT2 inhibitors, a class of diabetes drugs, may reduce the risk of Alzheimer’s, vascular dementia, and Parkinson’s disease, according to a large study. Results showed a 20% to 30% lower risk for these conditions,
Diabetes drugs may protect against dementia
New research shows diabetes drugs may significantly reduce the risk of dementia, Alzheimer's, and Parkinson’s disease.
SGLT2 inhibitors reduce dementia, Parkinson’s disease risk: study
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of diabetes drugs also known as gliflozins, could lower the risk for dementia and Parkinson’s disease, a new study finds.
Some diabetes meds might lower risk of dementia, Parkinson's
A specific class of diabetes drug appears to lower people's risk for dementia and Parkinson's disease, a new study shows.
These Diabetes Drugs Could Help Lower Your Risk of Dementia, Parkinson’s
According to a new study, certain diabetes medications may significantly reduce this risk. These drugs, called gliflozins or SGLT2 inhibitors, stop the kidneys from reabsorbing too much blood glucose to improve blood sugar levels.
SGLT2 inhibitors tied to lower risk of dementia, Parkinson's disease, suggests study
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a study published in the September 18, 2024, online issue of Neurology®,
Some Diabetes Drugs May Protect Against Dementia and Parkinson's
Scientists found a 22 percent lower risk of any dementia and Parkinson's among a group taking SGLT2 inhibitors for type 2 diabetes.
Type 2 drugs could lower dementia, Parkinson's disease risk
Researchers have found that people who take a type of type 2 diabetes drugs SGLT2 inhibitors have a significantly lower risk of dementia, overall, and of Alzheimer's disease and Parkinson's, in particular.
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease
A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease, according to a new study.
GlobalData on MSN22d
Diabetes duration has minimal impact on SGLT2 inhibitor efficacy, as per new analysis
A meta-analysis has demonstrated consistent efficacy in heart failure outcomes with SGLT2 inhibitors regardless of disease ...
News Medical on MSN8h
Research reveals disparities in diabetes drug efficacy for Black populations
New research analyzing the effects of two drugs used to treat type 2 diabetes indicates a consistent lack of cardiovascular and renal benefits in Black populations.
Medscape13d
Do SGLT2 Inhibitors Benefit Everyone With T2D and CKD?
New data suggest that current recommendations overstate the proportion of patients who would receive significant kidney ...
Daily12d
Study Reveals Significant Care Gap in SGLT2 Inhibitor Use for Diabetes and HF, Despite Real-World Benefits
Recent study highlights a significant care gap due to the underuse of SGLT2 inhibitors, despite their benefits. Canada: A ...